Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Masimo Corporation entered into an Agreement and Plan of Merger to be acquired by Danaher. In the merger, Mobius Merger Sub, Inc., a wholly owned Danaher subsidiary, will merge with and into Masimo, with Masimo surviving as a wholly owned Danaher subsidiary.
If the merger is completed, each share of Masimo common stock outstanding immediately prior to the effective time (excluding shares owned by Danaher, Merger Sub, or Masimo subsidiaries, and excluding dissenting shares) will be converted into the right to receive $180.00 in cash per share, without interest. The proxy also describes a Voting and Support Agreement with Politan Capital Management LP to vote covered shares in favor of the merger.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026